Femasys (FEMY) Net Equity Issued and Repurchased (2020 - 2025)
Femasys' (FEMY) quarterly Net Equity Issued and Repurchased came in at $3.5 million in Q4 2025, up 495.55% on a QoQ basis from -$882026.0 in Q2 2025.
Femasys (FEMY) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends
Femasys (FEMY) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $3.5 million in Q4 2025.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $3.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.0 million (up 1.28% YoY) and the FY2025 annual result came in at $8.0 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased rose to $3.5 million in Q4 2025, from -$882026.0 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $31.7 million in Q2 2021 to a low of -$882026.0 in Q2 2025.
- A 5-year average of $5.0 million and a median of $59583.0 in 2022 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased plunged 85.25% — and 2024, when it surged 257830.63%.
- Tracing FEMY's Net Equity Issued and Repurchased over 5 years: stood at $14401.0 in 2021, then soared by 313.74% to $59583.0 in 2022, then jumped by 12758.86% to $7.7 million in 2023, then sank by 110.47% to -$802242.0 in 2024, then jumped by 534.88% to $3.5 million in 2025.
- The last three Net Equity Issued and Repurchased figures came in at $3.5 million (Q4 2025), -$882026.0 (Q2 2025), and $5.4 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | - |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | - |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 29.31 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | - |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | - |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | - |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | - |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | - |
| 10 | Femasys | 9.97 Mn | 8.53 Mn | 189,391.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.49 Mn |
| Dec 31, 2025 | 3.49 Mn |
| Jun 30, 2025 | -882,026.00 |
| Jun 30, 2025 | -882,026.00 |
| Mar 31, 2025 | 5.39 Mn |
| Mar 31, 2025 | 5.39 Mn |
| Jun 30, 2024 | -802,242.00 |
| Jun 30, 2024 | -802,242.00 |
| Mar 31, 2024 | 8.70 Mn |
| Mar 31, 2024 | 8.70 Mn |
| Dec 31, 2023 | 7.66 Mn |
| Dec 31, 2023 | 7.66 Mn |
| Mar 31, 2023 | 3,373.00 |
| Mar 31, 2023 | 3,373.00 |
| Dec 31, 2022 | 59,583.00 |
| Dec 31, 2022 | 59,583.00 |
| Dec 31, 2021 | 14,401.00 |
| Dec 31, 2021 | 14,401.00 |
| Jun 30, 2021 | 31.72 Mn |
| Jun 30, 2021 | 31.72 Mn |